Author Topic: (Abst.) Epilepsy in MS: Nationwide population-based register study [Sweden]  (Read 93 times)

0 Members and 2 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed, November 10, 2017:

Quote
Neurology. 2017 Nov 8.

Epilepsy in multiple sclerosis: A nationwide population-based register study

Burman J1, Zelano J2.

Author information
1
From the Department of Neuroscience (J.B.), Uppsala University; and Department of Clinical Neuroscience (J.Z.), Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Sweden.
2
From the Department of Neuroscience (J.B.), Uppsala University; and Department of Clinical Neuroscience (J.Z.), Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Sweden. johan.zelano@neuro.gu.se.

OBJECTIVE:

To determine the cumulative incidence of epilepsy in a population-based cohort of patients with multiple sclerosis (MS) and to investigate the association between epilepsy and clinical features of MS.

METHODS:

All available patients in the Swedish MS register (n = 14,545) and 3 age- and sex-matched controls per patient randomly selected from the population register (n = 43,635) were included. Data on clinical features of MS were retrieved from the Swedish MS register, and data on epilepsy and death were retrieved from comprehensive patient registers.

RESULTS:

The cumulative incidence of epilepsy was 3.5% (95% confidence interval [CI] 3.17-3.76) in patients with MS and 1.4% (95% CI 1.30-1.52) in controls (risk ratio 2.5, 95% CI 2.19-2.76). In a Cox proportional model, MS increased the risk of epilepsy (hazard ratio 3.2, 95% CI 2.64-3.94). Patients with relapsing-remitting MS had a cumulative incidence of epilepsy of 2.2% (95% CI 1.88-2.50), whereas patients with progressive disease had a cumulative incidence of 5.5% (95% CI 4.89-6.09). The cumulative incidence rose continuously with increasing disease duration to 5.9% (95% CI 4.90-7.20) in patients with disease duration ≥34 years. Patients with an Expanded Disability Status Scale (EDSS) score ≥7 had a cumulative incidence of epilepsy of 5.3% (95% CI 3.95-7.00). Disease duration and EDSS score were associated with epilepsy after multiple logistic regression (odds ratio [OR] 1.03, 95% CI 1.01-1.04 per year, p = 0.001; and OR 1.2, 95% CI 1.09-1.26 per EDSS step, p < 0.0001).

CONCLUSIONS:


Epilepsy is more common among patients with MS than in the general population, and a diagnosis of MS increases the risk of epilepsy. Our data suggest a direct link between severity of MS and epilepsy.

https://www.ncbi.nlm.nih.gov/pubmed/29117950
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
101 Views
Last post December 13, 2016, 07:26:06 am
by agate
0 Replies
159 Views
Last post April 27, 2018, 02:07:54 pm
by agate
1 Replies
146 Views
Last post March 04, 2019, 09:36:37 pm
by agate
0 Replies
12 Views
Last post December 15, 2023, 04:44:56 pm
by agate
0 Replies
3 Views
Last post March 10, 2024, 09:11:35 pm
by agate